12-week 0.1% ciclosporin A eye drops to reduce immune cells on the eye surface in dry eye
Official title: The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Ocular Surface Innate and Adaptive Immune Response in Dry Eye Disease
Run by The University of New South Wales · NCT06898853 · Data updated 2026-11-12
This trial will try 0.1% ciclosporin A eye drops for people with dry eye to see if the drops reduce inflammatory immune cells on the eye surface compared with mineral oil drops.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | The University of New South Wales Academic / other |
| Locations | 1 site (Sydney, New South Wales) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT06898853 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and over with dry eye who meet at least two diagnostic criteria (OSDI ≥23, Oxford staining ≥1, or tear meniscus height <0.2 mm) and who are not using topical or systemic immunomodulators are ideal candidates.
✕Probably not a fit
Patients with cicatricial conjunctival disease (for example Stevens–Johnson syndrome), recent ocular surgery, active ocular infection, recent contact lens use, or recent use of topical/systemic anti-inflammatory eye treatments are unlikely to qualify or benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with dry eye who meet symptom and sign criteria will receive either 0.1% ciclosporin A eye drops or mineral oil drops for 12 weeks. Researchers will use in vivo confocal microscopy and conjunctival sampling to measure changes in immune cell populations and activation markers on the ocular surface. Participants must meet specific diagnostic thresholds for dry eye and must not have recent use of topical or systemic immunomodulatory therapies or certain ocular comorbidities. Outcomes focus on cellular and molecular changes rather than symptomatic endpoints alone, providing mechanistic information about how ciclosporin A affects ocular surface immunity.
Why it matters
Potential benefit: If successful, the trial could show that topical ciclosporin A reduces ocular surface inflammation and help tailor anti-inflammatory treatment for people with dry eye.
How similar studies have gone: Topical ciclosporin has previously shown improvements in signs and symptoms of dry eye in other trials, while using high-resolution imaging and cell phenotyping to track specific ocular surface immune-cell changes is a more novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years of age and above 2. Participants should meet any two of the following DED diagnostic criteria: i) ocular surface disease index score of ≥23 and ii) Oxford staining score of ≥1 iii) Tear meniscus height \< 0.2 mm. Exclusion Criteria: 1. Participants currently using or with previous use of steroids, ciclosporin, lifitegrast or any anti-inflammatory eye drops in the last 6 months. 2. Participants with systemic CsA or tacrolimus 3. Known hypersensitivity or contraindication to the study medication or any of its ingredients. 4. Active intraocular inflammation. 5. Contact lens wear or the use of contact lenses in the last 4 weeks. 6. Active eye infections or history of critical illness. 7. DED secondary to Steven-Johnson syndrome and cicatricial conjunctival disease. 8. Participants with other ocular co-morbidities and medications for glaucoma. 9. Participants with previous history of ocular surgery in the past 6 months. 10. Any other active or inactive systemic condition, structural abnormality such as eyelid malposition's that in the judgment of the investigator could confound study assessments or limit compliance. 11. Pregnant/breastfeeding women
Where it's running
-
School of Optometry and Vision Science
Sydney, New South Wales, Australia Recruiting
Study contacts
- Principal investigator: Fiona Stapleton Professor, PhD — The University of New South Wales
- Study coordinator: Fiona Stapleton Professor, PhD
- Email: f.stapleton@unsw.edu.au
- Phone: +61 0418868234
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can cyclosporine 0.1% eye drops improve comfort for contact lens wearers with dry eye
This study tests whether a water-free cyclosporine eye drop (VEVYE) can reduce dry eye symptoms and improve comfort for adults who wear soft contact lenses.
-
Association Between Periodontitis and Dry Eye Disease in Adults
This study tests whether periodontitis and dry eye disease are linked by comparing groups with and without each condition.
-
Brillouin hydration mapping to study cornea health
Researchers test a Brillouin microscope to see if it can measure corneal water content in healthy people and those with eye conditions.
-
Is Systane PRO Preservative Free as good as Blink Triple Care Preservative Free for dry eye symptoms
This study tests whether Systane PRO Preservative Free works as well as Blink Triple Care Preservative Free to improve dry eye symptoms in adults over 4 weeks.
-
TRYPTYR eye drops for dry eye disease
This study tests TRYPTYR eye drops to see if they improve dry eye symptoms in adults with Dry Eye Disease.
-
OTC lubricating eye drops for dry eye disease: tolerability and vision outcomes
This trial tests whether a preservative-free OTC eye drop mix can be tolerated and improve symptoms and visual comfort in adults with dry eye disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.